The use of polygenic risk scores to identify phenotypes associated with genetic risk of schizophrenia: Systematic review

被引:81
|
作者
Mistry, Sumit [1 ]
Harrison, Judith R. [1 ]
Smith, Daniel J. [2 ]
Escott-Price, Valentina [1 ]
Zammit, Stanley [1 ,3 ]
机构
[1] Cardiff Univ, MRC, Ctr Neuropsychiat Genet & Genom, Inst Psychol Med & Clin Neurosci, Cardiff, S Glam, Wales
[2] Univ Glasgow, Inst Hlth & Wellbeing, 1 Lilybank Gardens, Glasgow, Lanark, Scotland
[3] Univ Bristol, Sch Social & Community Med, Ctr Acad Mental Hlth, Bristol, Avon, England
关键词
Polygenic risk score; Schizophrenia; Genetic; Phenotypes; GENOME-WIDE ASSOCIATION; DEFICIT HYPERACTIVITY DISORDER; MAJOR PSYCHIATRIC-DISORDERS; BIPOLAR DISORDER; AUTOIMMUNE-DISEASES; DEPRESSIVE DISORDER; COMORBIDITY; CHILDHOOD; OVERLAP; ENDOPHENOTYPES;
D O I
10.1016/j.schres.2017.10.037
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Studying the phenotypic manifestations of increased genetic liability for schizophrenia can increase our understanding of this disorder. Specifically, information from alleles identified in genome-wide association studies can be collapsed into a polygenic risk score (PRS) to explore howgenetic risk ismanifestwithin different samples. In this systematic review, we provide a comprehensive assessment of studies examining associations between schizophrenia PRS (SZ-PRS) and several phenotypic measures. We searched EMBASE, Medline and PsycINFO (from August 2009-14th March 2016) plus references of included studies, following PRISMA guidelines. Study inclusion was based on predetermined criteria and data were extracted independently and in duplicate. Overall, SZ-PRS was associated with increased risk for psychiatric disorders such as depression and bipolar disorder, lower performance IQ and negative symptoms. SZ-PRS explained up to 6% of genetic variation in psychiatric phenotypes, compared to <0.7% in measures of cognition. Future gains fromusing the PRS approach may be greater if used for examining phenotypes that are more closely related to biological substrates, for scores based on genepathways, and where PRSs are used to stratify individuals for study of treatment response. As it was difficult to interpret findings across studies due to insufficient information provided by many studies, we propose a framework to guide robust reporting of PRS associations in the future. Crown Copyright (c) 2017 Published by Elsevier B. V. All rights reserved.
引用
收藏
页码:2 / 8
页数:7
相关论文
共 50 条
  • [21] Polygenic risk scores for schizophrenia and treatment resistance: New data, systematic review and meta-analysis
    Facal, Fernando
    Costas, Javier
    SCHIZOPHRENIA RESEARCH, 2023, 252 : 189 - 197
  • [22] How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis
    Siltari, Aino
    Lonnerbro, Ragnar
    Pang, Karl
    Shiranov, Kirill
    Asiimwe, Alex
    Evans-Axelsson, Susan
    Franks, Billy
    Kiran, Amit
    Murtola, Teemu J.
    Schalken, Jack
    Steinbeisser, Carl
    Bjartell, Anders
    PIONEER Consortium
    CLINICAL GENITOURINARY CANCER, 2023, 21 (02) : 316e1 - 316e11
  • [23] CAN POLYGENIC RISK SCORES HELP IDENTIFY PEDIATRIC BIPOLAR SPECTRUM AND RELATED DISORDERS? A SYSTEMATIC LITERATURE REVIEW
    Green, Allison
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2021, 60 (10): : S276 - S276
  • [24] CNVS AND POLYGENIC SCORES INTERACT TO CONTRIBUTE TO SCHIZOPHRENIA RISK
    Bergen, Sarah E.
    Howrigan, Daniel
    Sebat, Jonathan
    Neale, Benjamin
    Kendler, Kenneth
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S198 - S198
  • [25] The Relationship Between Polygenic Risk Scores and Cognition in Schizophrenia
    Richards, Alexander L.
    Pardinas, Antonio F.
    Frizzati, Aura
    Tansey, Katherine E.
    Lynham, Amy J.
    Holmans, Peter
    Legge, Sophie E.
    Savage, Jeanne E.
    Agartz, Ingrid
    Andreassen, Ole A.
    Blokland, Gabriella A. M.
    Corvin, Aiden
    Cosgrove, Donna
    Degenhardt, Franziska
    Djurovic, Srdjan
    Espeseth, Thomas
    Ferraro, Laura
    Gayer-Anderson, Charlotte
    Giegling, Ina
    van Haren, Neeltje E.
    Hartmann, Annette M.
    Hubert, John J.
    Jonsson, Erik G.
    Konte, Bettina
    Lennertz, Leonhard
    Loohuis, Loes M. Olde
    Melle, Ingrid
    Morgan, Craig
    Morris, Derek W.
    Murray, Robin M.
    Nyman, Hakan
    Ophoff, Roel A.
    van Os, Jim
    Petryshen, Tracey L.
    Quattrone, Diego
    Rietschel, Marcella
    Rujescu, Dan
    Rutten, Bart P. F.
    Streit, Fabian
    Strohmaier, Jana
    Sullivan, Patrick F.
    Sundet, Kjetil
    Wagner, Michael
    Escott-Price, Valentina
    Owen, Michael J.
    Donohoe, Gary
    O'Donovan, Michael C.
    Walters, James T. R.
    SCHIZOPHRENIA BULLETIN, 2020, 46 (02) : 336 - 344
  • [26] Polygenic Risk Scores in Schizophrenia: Ready for the Real World?
    Binder, Elisabeth B.
    AMERICAN JOURNAL OF PSYCHIATRY, 2019, 176 (10): : 783 - 784
  • [27] THE GENETIC ARCHITECTURE OF SCHIZOPHRENIA: HOW DO CNVS AND POLYGENIC SCORES CONTRIBUTE TO DISEASE RISK?
    Bergen, Sarah E.
    Smoller, Jordan
    Sebat, Jonathan
    Purcell, Shaun
    Neale, Benjamin
    Kendler, Kenneth
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S62 - S62
  • [28] Polygenic Risk Scores to Identify CVD Risk and Tailor Therapy: Hope or Hype?
    Charles A. German
    Michael D. Shapiro
    Current Atherosclerosis Reports, 2021, 23
  • [29] Polygenic Risk Scores to Identify CVD Risk and Tailor Therapy: Hope or Hype?
    German, Charles A.
    Shapiro, Michael D.
    CURRENT ATHEROSCLEROSIS REPORTS, 2021, 23 (09)
  • [30] ASSOCIATION OF SCHIZOPHRENIA POLYGENIC RISK SCORES WITH TREATMENT-RESISTANT SCHIZOPHRENIA
    Zai, Clement
    Teymouri, Kosar
    Ebrahimi, Mahbod
    Mohiuddin, Ayeshah
    Attaluri, Pratyusha
    Tampakeras, Maria
    Freeman, Natalie
    Zai, Gwyneth
    Mueller, Daniel
    Kennedy, James L.
    Tiwari, Arun K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2023, 75 : S206 - S206